1. Ventricular arrhythmia suppression with ivabradine in a patient with catecholaminergic polymorphic ventricular tachycardia refractory to nadolol, flecainide, and sympathectomy.
- Author
-
Kohli U, Aziz Z, Beaser AD, and Nayak HM
- Subjects
- Adolescent, Electrocardiography, Exercise Test, Flecainide therapeutic use, Humans, Male, Nadolol therapeutic use, Phenotype, Sympathectomy, Tachycardia, Ventricular surgery, Polymorphic Catecholaminergic Ventricular Tachycardia, Cardiovascular Agents therapeutic use, Ivabradine therapeutic use, Tachycardia, Ventricular drug therapy
- Abstract
Conventional treatment strategies for catecholaminergic polymorphic ventricular tachycardia (CPVT) include avoidance of strenuous exercise and competitive sports, drugs such as ß-blockers and flecainide and, cervical sympathectomy. An implantable cardioverter-defibrillator (ICD) has been utilized if the response to these strategies is inadequate; however, ICD use in CPVT patients, in addition to usual complications, is associated with an increased risk of life-threatening electrical storm. Ivabradine is a selective inhibitor of hyperpolarization-activated cyclic nucleotide-gated potassium channel 4 generated funny current (I
f ), which has been shown to be efficacious in suppression of inappropriate sinus tachycardia, junctional tachycardia, atrial tachycardia, and ventricular ectopy in humans. We report an 18-year-old male with a severe CPVT phenotype refractory to flecainide, nadolol, and sympathectomy who exhibited suppression of ventricular arrhythmias after initiation of ivabradine. These findings are of importance as ivabradine could be an important add-on therapy in CPVT patients who are drug refractory or are unable to continue conventional therapies at the recommended doses., (© 2020 Wiley Periodicals, Inc.)- Published
- 2020
- Full Text
- View/download PDF